Adaptimmune Therapeutics Plc Stock Price History
| ADAP Stock | USD 0.72 0.01 1.37% |
Below is the normalized historical share price chart for Adaptimmune Therapeutics Plc extending back to May 06, 2015. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Adaptimmune Therapeutics stands at 0.72, as last reported on the 2nd of December, with the highest price reaching 0.74 and the lowest price hitting 0.72 during the day.
If you're considering investing in Adaptimmune Stock, it is important to understand the factors that can impact its price. Adaptimmune Therapeutics secures Sharpe Ratio (or Efficiency) of -0.15, which signifies that the company had a -0.15% return per unit of standard deviation over the last 3 months. Adaptimmune Therapeutics Plc exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Adaptimmune Therapeutics' mean deviation of 3.12, and Risk Adjusted Performance of (0.10) to double-check the risk estimate we provide.
At this time, Adaptimmune Therapeutics' Common Stock Total Equity is relatively stable compared to the past year. As of 12/02/2024, Common Stock is likely to grow to about 2 M, while Total Stockholder Equity is likely to drop slightly above 37.5 M. . At this time, Adaptimmune Therapeutics' Price Book Value Ratio is relatively stable compared to the past year. As of 12/02/2024, Price Earnings To Growth Ratio is likely to grow to 0.03, while Price To Operating Cash Flows Ratio is likely to drop (1.19). Adaptimmune Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 6th of May 2015 | 200 Day MA 1.1021 | 50 Day MA 0.8072 | Beta 2.247 |
Adaptimmune |
Sharpe Ratio = -0.1499
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ADAP |
Estimated Market Risk
| 4.64 actual daily | 41 59% of assets are more volatile |
Expected Return
| -0.7 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Adaptimmune Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Adaptimmune Therapeutics by adding Adaptimmune Therapeutics to a well-diversified portfolio.
Price Book 2.3055 | Enterprise Value Ebitda (1.71) | Price Sales 1.3114 | Shares Float 1 B | Wall Street Target Price 2.2667 |
Adaptimmune Therapeutics Stock Price History Chart
There are several ways to analyze Adaptimmune Stock price data. The simplest method is using a basic Adaptimmune candlestick price chart, which shows Adaptimmune Therapeutics price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
| Highest Price | September 9, 2024 | 1.11 |
| Lowest Price | November 14, 2024 | 0.59 |
Adaptimmune Therapeutics December 2, 2024 Stock Price Synopsis
Various analyses of Adaptimmune Therapeutics' daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell Adaptimmune Stock. It can be used to describe the percentage change in the price of Adaptimmune Therapeutics from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of Adaptimmune Stock.| Adaptimmune Therapeutics Price Daily Balance Of Power | (0.50) | |
| Adaptimmune Therapeutics Price Action Indicator | (0.02) | |
| Adaptimmune Therapeutics Price Rate Of Daily Change | 0.99 |
Adaptimmune Therapeutics December 2, 2024 Stock Price Analysis
Adaptimmune Stock Price History Data
The price series of Adaptimmune Therapeutics for the period between Tue, Sep 3, 2024 and Mon, Dec 2, 2024 has a statistical range of 0.68 with a coefficient of variation of 19.23. The prices are distributed with arithmetic mean of 0.88. The median price for the last 90 days is 0.87. The company issued dividends on 2018-03-30.| Open | High | Low | Close | Volume | ||
12/02/2024 | 0.73 | 0.74 | 0.72 | 0.72 | ||
| 11/29/2024 | 0.73 | 0.74 | 0.72 | 0.72 | 220,906 | |
| 11/27/2024 | 0.69 | 0.73 | 0.68 | 0.73 | 3,316,106 | |
| 11/26/2024 | 0.71 | 0.71 | 0.68 | 0.68 | 386,493 | |
| 11/25/2024 | 0.68 | 0.71 | 0.66 | 0.70 | 1,434,816 | |
| 11/22/2024 | 0.63 | 0.66 | 0.60 | 0.66 | 1,341,570 | |
| 11/21/2024 | 0.66 | 0.68 | 0.63 | 0.64 | 787,068 | |
| 11/20/2024 | 0.68 | 0.71 | 0.64 | 0.66 | 4,158,925 | |
| 11/19/2024 | 0.60 | 0.68 | 0.57 | 0.67 | 5,451,422 | |
| 11/18/2024 | 0.60 | 0.64 | 0.58 | 0.60 | 1,794,113 | |
| 11/15/2024 | 0.59 | 0.61 | 0.58 | 0.59 | 5,185,940 | |
| 11/14/2024 | 0.81 | 0.81 | 0.58 | 0.59 | 14,516,677 | |
| 11/13/2024 | 0.82 | 0.83 | 0.75 | 0.77 | 1,545,050 | |
| 11/12/2024 | 0.82 | 0.82 | 0.76 | 0.79 | 568,531 | |
| 11/11/2024 | 0.81 | 0.83 | 0.78 | 0.82 | 741,070 | |
| 11/08/2024 | 0.78 | 0.80 | 0.75 | 0.80 | 687,532 | |
| 11/07/2024 | 0.82 | 0.83 | 0.77 | 0.78 | 725,444 | |
| 11/06/2024 | 0.82 | 0.86 | 0.79 | 0.83 | 653,371 | |
| 11/05/2024 | 0.82 | 0.83 | 0.79 | 0.83 | 444,528 | |
| 11/04/2024 | 0.80 | 0.86 | 0.78 | 0.83 | 1,237,535 | |
| 11/01/2024 | 0.73 | 0.82 | 0.73 | 0.80 | 1,107,578 | |
| 10/31/2024 | 0.71 | 0.75 | 0.70 | 0.73 | 1,242,369 | |
| 10/30/2024 | 0.70 | 0.72 | 0.67 | 0.70 | 2,797,477 | |
| 10/29/2024 | 0.74 | 0.75 | 0.70 | 0.70 | 820,933 | |
| 10/28/2024 | 0.74 | 0.77 | 0.73 | 0.74 | 1,341,177 | |
| 10/25/2024 | 0.75 | 0.79 | 0.72 | 0.74 | 1,700,093 | |
| 10/24/2024 | 0.78 | 0.78 | 0.74 | 0.75 | 1,180,521 | |
| 10/23/2024 | 0.83 | 0.85 | 0.78 | 0.78 | 737,466 | |
| 10/22/2024 | 0.82 | 0.83 | 0.80 | 0.81 | 1,244,133 | |
| 10/21/2024 | 0.84 | 0.85 | 0.82 | 0.82 | 962,439 | |
| 10/18/2024 | 0.86 | 0.87 | 0.84 | 0.84 | 750,813 | |
| 10/17/2024 | 0.88 | 0.88 | 0.84 | 0.84 | 868,142 | |
| 10/16/2024 | 0.89 | 0.90 | 0.87 | 0.87 | 1,127,936 | |
| 10/15/2024 | 0.87 | 0.90 | 0.87 | 0.88 | 1,811,444 | |
| 10/14/2024 | 0.88 | 0.89 | 0.83 | 0.88 | 1,781,243 | |
| 10/11/2024 | 0.89 | 0.91 | 0.86 | 0.87 | 773,137 | |
| 10/10/2024 | 0.88 | 0.89 | 0.87 | 0.88 | 210,147 | |
| 10/09/2024 | 0.90 | 0.91 | 0.86 | 0.89 | 1,975,552 | |
| 10/08/2024 | 0.91 | 0.94 | 0.91 | 0.91 | 371,632 | |
| 10/07/2024 | 0.94 | 0.96 | 0.90 | 0.91 | 526,848 | |
| 10/04/2024 | 0.90 | 0.96 | 0.89 | 0.95 | 730,145 | |
| 10/03/2024 | 0.87 | 0.91 | 0.86 | 0.90 | 1,367,141 | |
| 10/02/2024 | 0.91 | 0.92 | 0.87 | 0.87 | 1,892,303 | |
| 10/01/2024 | 0.94 | 0.95 | 0.91 | 0.92 | 557,601 | |
| 09/30/2024 | 0.98 | 1.00 | 0.93 | 0.95 | 491,236 | |
| 09/27/2024 | 0.96 | 1.01 | 0.94 | 0.98 | 841,923 | |
| 09/26/2024 | 0.93 | 0.95 | 0.91 | 0.94 | 1,006,255 | |
| 09/25/2024 | 0.97 | 0.99 | 0.91 | 0.92 | 1,760,472 | |
| 09/24/2024 | 0.95 | 0.99 | 0.95 | 0.97 | 613,889 | |
| 09/23/2024 | 1.00 | 1.00 | 0.87 | 0.94 | 2,229,888 | |
| 09/20/2024 | 1.03 | 1.03 | 0.98 | 1.00 | 840,615 | |
| 09/19/2024 | 1.03 | 1.06 | 1.00 | 1.01 | 918,308 | |
| 09/18/2024 | 1.03 | 1.07 | 1.02 | 1.04 | 963,677 | |
| 09/17/2024 | 1.09 | 1.09 | 1.04 | 1.05 | 958,492 | |
| 09/16/2024 | 1.12 | 1.12 | 1.03 | 1.05 | 1,548,923 | |
| 09/13/2024 | 1.13 | 1.17 | 1.10 | 1.11 | 943,748 | |
| 09/12/2024 | 1.09 | 1.11 | 1.08 | 1.10 | 766,120 | |
| 09/11/2024 | 1.10 | 1.10 | 1.07 | 1.08 | 440,623 | |
| 09/10/2024 | 1.09 | 1.11 | 1.06 | 1.08 | 793,807 | |
| 09/09/2024 | 1.08 | 1.16 | 1.08 | 1.11 | 655,153 | |
| 09/06/2024 | 1.10 | 1.15 | 1.08 | 1.09 | 1,002,881 |
About Adaptimmune Therapeutics Stock history
Adaptimmune Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Adaptimmune is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Adaptimmune Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Adaptimmune Therapeutics stock prices may prove useful in developing a viable investing in Adaptimmune Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 201.1 M | 129.5 M | |
| Net Loss | -148.9 M | -141.5 M |
Adaptimmune Therapeutics Quarterly Net Working Capital |
|
Adaptimmune Therapeutics Stock Technical Analysis
Adaptimmune Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run Portfolio Holdings Now
Portfolio HoldingsCheck your current holdings and cash postion to detemine if your portfolio needs rebalancing |
| All Next | Launch Module |
Adaptimmune Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Adaptimmune Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Adaptimmune Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Adaptimmune to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.10) | |||
| Jensen Alpha | (0.87) | |||
| Total Risk Alpha | (1.47) | |||
| Treynor Ratio | (0.51) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.